[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.197.90.95. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Article
February 1975

Intralesional Triamcinolone Therapy for Pretibial Myxedema

Author Affiliations

From the Department of Dermatology (Dr. Lang) and the Section of Nuclear Medicine (Dr. Sisson), University of Michigan Medical Center, Ann Arbor, Michigan, and the Division of Dermatology, Department of Internal Medicine, University of Arizona Medical Center, Tucson, Arizona (Dr. Lynch).

Arch Dermatol. 1975;111(2):197-202. doi:10.1001/archderm.1975.01630140055005
Abstract

In a prospective study, nine patients with pretibial myxedema were treated with intralesional injections of triamcinolone acetonide. Complete resolution of the myxedematous plaques was obtained in seven of the nine patients. The other two patients failed to complete their treatment programs but did show partial resolution. For most patients the monthly injection of 8 ml or less of a solution containing 5 mg/ml of triamcinolone proved to be the most effective dosage schedule. No serious side effects were encountered. New nodules of myxedema developed in some patients after the initial completion of therapy; these nodules responded to reinjection using the same dosage schedule.

×